Cardiovascular prevention: early and consistent prevention versus late intervention, complex approach to the treatment of modifiable risk factors: hypertension and dyslipidemia
Authors:
Lukáš Zlatohlávek
Authors‘ workplace:
3. interní klinika 1. LF UK a VFN, Praha
Published in:
Vnitř Lék 2021; 67(7): 412-418
Category:
Review Articles
Overview
Cardiovascular diseases (not including COVID-19 infection) are still one of the most common causes of mortality and morbidity in our country and in developed countries. Today no one questions the intervention of all risk factors for atherosclerosis after a cardiovascular event, although unfortunately even in this case the recommended target values are often not achieved. However, the intervention of risk factors in primary prevention is often neglected. Atherosclerosis is a long-term process, developing since the childhood. It is a continuous process and the event itself is only the culmination of this process. Therefore, it is necessary to intervene in key risk factors early in life, and we have ample evidence that even early pharmacological intervention has a clear effect on slowing or stopping the process of atherosclerosis.
Keywords:
arterial hypertension – dyslipidemia – early intervention – risk factors of atherosclerosis
Sources
1. www.czso.cz
2. Zhang Y et al. Associations of Blood Pressre and Choelsterol levels During Young Adulthood With Later Cardiovaskular Events, J Am cool Cardiol 2019 July 23; 74(3): 330–341.
3. Ference et al. Association of Genetic Variants Related to Combined Exposure to Lower Low‑Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease, JAMA, 2/2019, E 1–11.
4. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, European Heart Journal (2019) 00, 1–78.
5. SCORE2 working group and ESC Cardiovascular risk collaboration: SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2439–2454.
6. SCORE2-OP working group and ESC Cardiovascular risk collaboration: SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2455–2467.
7. Sabatine MS, Giugliano RP, Keech AC, for the FO RIER Steering Committee and Investigators: Evolocumab and Clincal Ou comes in Patients with Cardiovascular Disease, N Engl J Med 2017; 376:1713–1722.
8. Feron O, Dessy C, Desager JP et al. Hydroxy‑methylglutaryl‑coenzyme A inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveoline abundance. Circulation 2001; 103: 113–118.
9. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582–587.
10. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O‘Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‑than‑average cholesterol concentrations, in the Anglo‑Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT‑LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5; 361(9364): 1149–1158.
11. Gupta A, Mackay J, Whitehouse A et al. ASCOT Legacy study. Lancet 2018; 392: 1127–1137.
12. Widimský J jr, Filipovský J, Ceral F et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017, Hypertenze a kardiovaskulární prevence, Supplementum, 2017.
13. Zlatohlávek L et al. Klinická dietologie a výživa, CurrentMedia, Praha, 2016.
14. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40: 326–345.
15. Fox KM. The EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double‑blind, placebo‑controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
16. Bruining N, deWinter S, Roaelandt JR et al. The Perspective study, Coron Artery Dis 2009, 20: 409–414.
17. Špinar J, Vítovec J. Studie ADVANCE. Remedia 2008; 18: 168–170.
18. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin‑converting enzyme inhibitors reduce mortality in hypertension: a meta‑analysis of randomized clinical trials of renin‑angiotensin‑aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33: 2088–2097.
19. Bruno et al. Early and Supernormal VAscular Aging, Hypertension, 2020; 76: 1–9.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2021 Issue 7
Most read in this issue
- Hereditary hemorrhagic telangiectasia (Osler‑Weber‑Rendu syndrome) – Part II. Pharmacological therapy and international guidelines for the therapy 2020
- Appropriate and inappropriate therapies of implantable cardioverter‑defibrillators
- Metabolic and endocrine diseases – is our approach always rational?
- First zero contrast PCI guided by intracoronary ultrasound in the Czech Republic